Apogee director exits 20,000 shares in merger
Apogee Therapeutics director Mark C. McKenna exchanged vested options and common shares for cash in a merger, leaving no directly held common stock.
Rhea-AI Filing Summary
Apogee Therapeutics, Inc. (APGE) director Mark C. McKenna reported dispositions of company securities in connection with a merger. On September 3, 2026, he returned vested stock options covering 150,000, 10,370, 14,461 and 7,657 shares of common stock to the issuer, with exercise prices of $23.60, $43.85, $41.66 and $85.00, respectively. Each option was cashed out under an Agreement and Plan of Merger at $135.11 per share of merger consideration, reduced by the relevant exercise price. In a related transaction, 20,000 shares of common stock were also disposed of pursuant to the same merger agreement, and his directly held common stock position became 0 shares after the transaction. The filing states that these options were vested or became fully vested in connection with the merger and that no Rule 10b5-1 trading plan is reported.
Positive
- None.
Negative
- None.
Insider Trade Summary
Disposition: 202,488 shares
Disposition
5 txns
Insider
McKenna Mark C.
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Stock Option (Right to Buy) F3, F2 | 150,000 | -- | -- |
| Disposition | Stock Option (Right to Buy) F3, F2 | 10,370 | -- | -- |
| Disposition | Stock Option (Right to Buy) F3, F2 | 14,461 | -- | -- |
| Disposition | Stock Option (Right to Buy) F3, F2 | 7,657 | -- | -- |
| Disposition | Common Stock F1 | 20,000 | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 0 contracts (Direct);
Common Stock — 0 shares (Direct)
Footnotes (3)
- F1. The reported securities represent shares of the Issuer's common stock disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of June 18, 2026 (the "Merger Agreement"), among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc.
- F2. The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger.
- F3. Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option.
Key Figures
Common stock disposed: 20,000 shares
Stock options disposed (first grant): 150,000 options
Stock options disposed (second grant): 10,370 options
+5 more
8 metrics
Common stock disposed
20,000 shares
Shares of Apogee Therapeutics common stock returned to the issuer on September 3, 2026 pursuant to the merger agreement
Stock options disposed (first grant)
150,000 options
Vested option covering 150,000 shares of common stock disposed to the issuer on September 3, 2026
Stock options disposed (second grant)
10,370 options
Vested option covering 10,370 shares of common stock disposed to the issuer on September 3, 2026
Stock options disposed (third grant)
14,461 options
Vested option covering 14,461 shares of common stock disposed to the issuer on September 3, 2026
Stock options disposed (fourth grant)
7,657 options
Vested option covering 7,657 shares of common stock disposed to the issuer on September 3, 2026
Per share merger consideration
$135.11 per share
Cash consideration used to calculate payments for each option under the merger agreement
Option exercise prices
$23.60, $43.85, $41.66, $85.00
Exercise prices for the four disposed stock option grants cashed out under the merger agreement
Direct common stock after transaction
0 shares
Directly held Apogee Therapeutics common stock reported after the merger-related disposition
Key Terms
Agreement and Plan of Merger, per share merger consideration, common stock, stock option, +1 more
5 terms
Agreement and Plan of Merger regulatory
"pursuant to the terms of the Agreement and Plan of Merger, dated as of June 18, 2026"
An Agreement and Plan of Merger is a formal document where two companies agree to combine into one, outlining how the process will happen. It’s like a step-by-step plan for merging, and it matters because it shows both sides have agreed on the details before the official transition takes place.
common stock financial
"shares of the Issuer's common stock disposed of pursuant to the terms of the Agreement and Plan of Merger"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
stock option financial
"The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger."
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
vested financial
"The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger."
FAQ
What did Apogee Therapeutics (APGE) director Mark C. McKenna report on this Form 4?
He reported dispositions of stock options and common stock on September 3, 2026, returning vested options and 20,000 common shares to Apogee Therapeutics in connection with a merger, with the options cashed out for cash based on per share merger consideration.
What happened to Mark C. McKenna’s Apogee (APGE) stock options in the merger?
Vested options over 150,000, 10,370, 14,461, and 7,657 shares of Apogee common stock were disposed of to the issuer and exchanged for cash equal to the $135.11 per share merger consideration minus each option’s exercise price.
What exercise prices applied to the Apogee (APGE) options cashed out for Mark C. McKenna?
The reported options had exercise prices of $23.60, $43.85, $41.66, and $85.00 per share, and each was exchanged for a cash payment equal to the per share merger consideration of $135.11 minus the respective exercise price.
Were Mark C. McKenna’s Apogee (APGE) Form 4 transactions under a Rule 10b5-1 plan?
No. The filing indicates that no Rule 10b5-1 trading plan is reported for these transactions; instead, the dispositions occurred pursuant to the terms of an Agreement and Plan of Merger dated June 18, 2026.
Did Mark C. McKenna’s Apogee (APGE) options vest in connection with the merger?
Yes. The filing explains that the reported options were vested as of the date of the merger or became fully vested in connection with the merger, and then were disposed of for cash under the merger agreement.
AI-generated analysis. How Rhea-AI works. Not financial advice.
